Pulse Biosciences price to book ratio PLSE

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 38.0×
10-year median: 9.6×
Against its 10-year history: 97th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.0× to 48.8×
Peer median: 4.4×

Pulse Biosciences' price to book ratio is 38.0× as of Oct 23, 2026.

That is above its ten-year median of 9.6×, higher than on 97% of days in the last ten years.

Over that time it ranged from 2.0× in May 2022 to 48.8× in Aug 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 4.4×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	38.0×	9.8×	38.6×
2025	10.5×	8.4×	16.9×
2024	14.0×	8.5×	48.8×
2023	12.9×	3.7×	23.3×
2022	16.7×	2.0×	17.4×
2021	9.3×	9.3×	34.2×
2020	18.5×	2.9×	18.5×
2019	6.9×	3.9×	11.7×
2018	6.9×	4.7×	8.4×
2017	7.7×	3.0×	18.1×
2016	3.1×	2.0×	5.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest Pulse Biosciences' size, closest first, today.

Company	Price to book ratio
PLSEPulse Biosciences	38.0×
NVSTEnvista	1.2×
ICUIICU Medical	1.9×
BMIBadger Meter	6.4×
WRBYWarby Parker	8.2×
VNTVontier	3.9×
ATRCAtriCure	5.8×
HAEHaemonetics	6.4×
MMSIMerit Medical Systems	3.3×
UFPTUFP Technologies	5.0×
INSPInspire Medical Systems	2.5×
Peer median	4.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Pulse Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.